{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Ramucirumab+DP", "query": { "intervention": "Ramucirumab DP" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 6, "total_pages": 1, "next_page_url": null, "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-11T20:04:15.214Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06616584", "title": "Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Recurrent Lung Non-Small Cell Carcinoma", "Stage IV Lung Cancer AJCC v8" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Cemiplimab", "type": "BIOLOGICAL" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Ramucirumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL", "DRUG" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 378, "start_date": "2025-05-22", "completion_date": "2028-12-31", "has_results": false, "last_update_posted_date": "2026-05-05", "last_synced_at": "2026-09-11T20:04:15.214Z", "location_count": 386, "location_summary": "Daphne, Alabama • Fairhope, Alabama • Mobile, Alabama + 316 more", "locations": [ { "city": "Daphne", "state": "Alabama" }, { "city": "Fairhope", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Saraland", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT06616584" }, { "nct_id": "NCT05096663", "title": "Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Advanced Lung Non-Small Cell Carcinoma", "Recurrent Lung Non-Small Cell Carcinoma", "Stage III Lung Cancer AJCC v8", "Stage IIIA Lung Cancer AJCC v8", "Stage IIIB Lung Cancer AJCC v8", "Stage IIIC Lung Cancer AJCC v8", "Stage IV Lung Cancer AJCC v8", "Stage IVA Lung Cancer AJCC v8", "Stage IVB Lung Cancer AJCC v8" ], "interventions": [ { "name": "Cobalamin", "type": "DIETARY_SUPPLEMENT" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Folic Acid", "type": "DIETARY_SUPPLEMENT" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Nogapendekin Alfa", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Ramucirumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DIETARY_SUPPLEMENT", "DRUG", "BIOLOGICAL" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 82, "start_date": "2022-03-15", "completion_date": "2027-12-01", "has_results": false, "last_update_posted_date": "2026-05-18", "last_synced_at": "2026-09-11T20:04:15.214Z", "location_count": 350, "location_summary": "Birmingham, Alabama • Goodyear, Arizona • Little Rock, Arkansas + 280 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Goodyear", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" }, { "city": "Arroyo Grande", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05096663" }, { "nct_id": "NCT01170663", "title": "A Study of Paclitaxel With or Without Ramucirumab (IMC-1211B) in Metastatic Gastric Adenocarcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Gastric Cancer" ], "interventions": [ { "name": "Ramucirumab (IMC-1211B) DP", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 665, "start_date": "2010-12", "completion_date": "2017-02", "has_results": true, "last_update_posted_date": "2019-09-18", "last_synced_at": "2026-09-11T20:04:15.214Z", "location_count": 13, "location_summary": "Burbank, California • Los Angeles, California • San Francisco, California + 10 more", "locations": [ { "city": "Burbank", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Miramar", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01170663" }, { "nct_id": "NCT01234402", "title": "Study of Icrucumab (IMC-18F1) or Ramucirumab Drug Product (DP) in Combination With Capecitabine or Capecitabine on Previously Treated Breast Cancer Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Ramucirumab DP", "type": "BIOLOGICAL" }, { "name": "IMC-18F1", "type": "BIOLOGICAL" }, { "name": "Capecitabine", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 153, "start_date": "2011-03", "completion_date": "2017-07", "has_results": true, "last_update_posted_date": "2019-08-14", "last_synced_at": "2026-09-11T20:04:15.214Z", "location_count": 20, "location_summary": "Scottsdale, Arizona • Los Angeles, California • Jacksonville, Florida + 17 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Augusta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01234402" }, { "nct_id": "NCT01282463", "title": "Study of Ramucirumab or Icrucumab (IMC-18F1) With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis Carcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Carcinoma of Urinary Tract", "Urethral Carcinoma", "Carcinoma of Ureter", "Carcinoma of Renal Pelvis" ], "interventions": [ { "name": "Docetaxel", "type": "DRUG" }, { "name": "Ramucirumab DP", "type": "BIOLOGICAL" }, { "name": "Icrucumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 148, "start_date": "2011-04", "completion_date": "2015-03", "has_results": true, "last_update_posted_date": "2019-09-09", "last_synced_at": "2026-09-11T20:04:15.214Z", "location_count": 26, "location_summary": "Los Angeles, California • Sacramento, California • San Francisco, California + 23 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT01282463" }, { "nct_id": "NCT01140347", "title": "A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatocellular Carcinoma" ], "interventions": [ { "name": "Placebo", "type": "BIOLOGICAL" }, { "name": "Ramucirumab DP (IMC-1121B)", "type": "BIOLOGICAL" }, { "name": "BSC", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 565, "start_date": "2010-10", "completion_date": "2015-03", "has_results": true, "last_update_posted_date": "2015-12-28", "last_synced_at": "2026-09-11T20:04:15.214Z", "location_count": 18, "location_summary": "Orange, California • San Francisco, California • New Haven, Connecticut + 15 more", "locations": [ { "city": "Orange", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "New Orleans", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT01140347" } ] }